Insider Transactions in Q4 2025 at Jazz Pharmaceuticals PLC (JAZZ)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Mary Elizabeth Henderson SVP, Technical Operations |
SELL
Open market or private sale
|
Direct |
2,238
-10.29%
|
$378,222
$169.51 P/Share
|
|
Dec 05
2025
|
Renee D Gala President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
80
-0.07%
|
$13,280
$166.91 P/Share
|
|
Dec 05
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,660
-20.66%
|
$796,860
$171.15 P/Share
|
|
Dec 05
2025
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+28.1%
|
$630,000
$140.67 P/Share
|
|
Dec 02
2025
|
Kenneth W O'Keefe Director |
SELL
Payment of exercise price or tax liability
|
Direct |
603
-2.28%
|
$104,319
$173.07 P/Share
|
|
Nov 26
2025
|
Bruce C Cozadd Director |
SELL
Open market or private sale
|
Direct |
77,500
-4.33%
|
$13,795,000
$178.59 P/Share
|
|
Nov 26
2025
|
Bruce C Cozadd Director |
BUY
Exercise of conversion of derivative security
|
Direct |
77,500
+7.1%
|
$9,532,500
$123.36 P/Share
|
|
Nov 20
2025
|
Heather Ann Mc Sharry Director |
SELL
Open market or private sale
|
Direct |
3,415
-14.31%
|
$604,455
$177.78 P/Share
|
|
Nov 20
2025
|
Heather Ann Mc Sharry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,415
+12.52%
|
$471,270
$138.08 P/Share
|
|
Nov 20
2025
|
Bruce C Cozadd Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,506
+0.63%
|
-
|
|
Nov 19
2025
|
Mary Elizabeth Henderson SVP, Technical Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,331
-5.77%
|
$239,580
$180.4 P/Share
|
|
Nov 18
2025
|
Bruce C Cozadd Director |
SELL
Open market or private sale
|
Direct |
18,000
-1.12%
|
$3,258,000
$181.35 P/Share
|
|
Nov 18
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,319
-21.89%
|
$962,739
$181.87 P/Share
|
|
Nov 18
2025
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,250
+29.98%
|
$714,000
$136.18 P/Share
|
|
Nov 18
2025
|
Rick E Winningham Director |
SELL
Open market or private sale
|
Direct |
5,500
-38.21%
|
$990,000
$180.86 P/Share
|
|
Nov 17
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
SELL
Open market or private sale
|
Direct |
7,159
-8.97%
|
$1,202,712
$168.26 P/Share
|
|
Oct 03
2025
|
Bruce C Cozadd Director |
SELL
Open market or private sale
|
Direct |
3,500
-0.85%
|
$490,000
$140.0 P/Share
|
|
Oct 01
2025
|
Bruce C Cozadd Director |
SELL
Open market or private sale
|
Direct |
2,000
-0.48%
|
$262,000
$131.78 P/Share
|